Aromatase inhibitors for breast cancer: lessons from the laboratory

Endocrine therapy with tamoxifen has been the mainstay of treatment for hormone-sensitive breast cancer for more than 20 years. An alternative strategy of oestrogen deprivation in postmenopausal women with aromatase inhibitors is set to replace tamoxifen based on better efficacy and a delay in the emergence of endocrine resistance. There are fundamental differences in how tamoxifen and aromatase inhibitors alter oestrogen-receptor signalling. Understanding the response and resistance to these different therapies is central to further improving therapeutic options for women with breast cancer.

[1]  D. Wolf,et al.  The estrogen receptor from a tamoxifen stimulated MCF-7 tumor variant contains a point mutation in the ligand binding domain , 2004, Breast Cancer Research and Treatment.

[2]  P. Chambon,et al.  Functional domains of the human estrogen receptor , 1987, Cell.

[3]  M. Dowsett,et al.  Aromatization inhibition alone or in combination with GnRH agonists for the treatment of premenopausal breast cancer patients , 1992, The Journal of Steroid Biochemistry and Molecular Biology.

[4]  P. Lønning,et al.  Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  Mitch Dowsett,et al.  Aromatase inhibitors in breast cancer. , 2003, The New England journal of medicine.

[6]  Ji-ping Wang,et al.  Role of MAP kinase in the enhanced cell proliferation of long term estrogen deprived human breast cancer cells , 2000, Breast Cancer Research and Treatment.

[7]  J. Cuzick,et al.  Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial , 2002, The Lancet.

[8]  M. Dowsett,et al.  Idoxifene antagonizes estradiol-dependent MCF-7 breast cancer xenograft growth through sustained induction of apoptosis. , 1999, Cancer research.

[9]  M. Ellis,et al.  Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  Simak Ali,et al.  Endocrine-responsive breast cancer and strategies for combating resistance , 2002, Nature Reviews Cancer.

[11]  B. Ponder,et al.  Polymorphisms in the human aromatase cytochrome P450 gene (CYP19) and breast cancer risk. , 2000, Carcinogenesis.

[12]  W. Miller,et al.  Analysis of the aromatase cytochrome P450 gene in human breast cancers. , 1994, Journal of molecular endocrinology.

[13]  P. Dombernowsky,et al.  Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  D. McDonnell,et al.  Definition of the molecular and cellular mechanisms underlying the tissue-selective agonist/antagonist activities of selective estrogen receptor modulators. , 2002, Recent progress in hormone research.

[15]  C. Osborne,et al.  Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu , 1992, Breast Cancer Research and Treatment.

[16]  G. T. Budd,et al.  Estrogen receptor mutations in tamoxifen-resistant breast cancer. , 1994, Cancer research.

[17]  A. Buzdar,et al.  Anastrozole is superior to tamoxifen as first‐line therapy in hormone receptor positive advanced breast carcinoma , 2001, Cancer.

[18]  M. Dowsett,et al.  Time‐related effects of estrogen withdrawal on proliferation‐ and cell death‐related events in MCF‐7 xenografts , 1999, International journal of cancer.

[19]  S. Hilsenbeck,et al.  Oxidative stress and AP-1 activity in tamoxifen-resistant breast tumors in vivo. , 2000, Journal of the National Cancer Institute.

[20]  R. Nicholson,et al.  Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells. , 2003, Endocrinology.

[21]  L. Melton,et al.  Role of Low Levels of Endogenous Estrogen in Regulation of Bone Resorption in Late Postmenopausal Women , 2002, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[22]  C K Osborne,et al.  Selective estrogen receptor modulators: structure, function, and clinical use. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  A. Howell,et al.  Effects of 4-hydroxytamoxifen and a novel pure antioestrogen (ICI 182780) on the clonogenic growth of human breast cancer cells in vitro. , 1994, British Journal of Cancer.

[24]  I. Bièche,et al.  Expression analysis of estrogen receptor alpha coregulators in breast carcinoma: evidence that NCOR1 expression is predictive of the response to tamoxifen. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[25]  M. Dowsett,et al.  Oestrogen receptor mutants and variants in breast cancer. , 1997, European journal of cancer.

[26]  D B Evans,et al.  Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  G. Chetrite,et al.  Concentrations of estrone, estradiol, and estrone sulfate and evaluation of sulfatase and aromatase activities in pre- and postmenopausal breast cancer patients. , 1996, The Journal of clinical endocrinology and metabolism.

[28]  A. Børresen-Dale,et al.  Screening for ESR mutations in breast and ovarian cancer patients , 1997, Human mutation.

[29]  Rakesh Kumar,et al.  Estradiol Hypersensitivity and Mitogen-Activated Protein Kinase Expression in Long-Term Estrogen Deprived Human Breast Cancer Cells in Vivo1. , 2000, Endocrinology.

[30]  S. Glück.  Anastrozole Is Superior to Tamoxifen as First-Line Therapy in Hormone Receptor Positive Advanced Breast Carcinoma Results of Two Randomized Trials Designed for Combined Analysis , 2001 .

[31]  M. Dowsett.  Theoretical considerations for the ideal aromatase inhibitor , 2004, Breast Cancer Research and Treatment.

[32]  A. Bitonti,et al.  Progression of MCF-7 breast cancer cells to antiestrogen-resistant phenotype is accompanied by elevated levels of AP-1 DNA-binding activity. , 1996, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[33]  A. Howell,et al.  Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  M. Dowsett,et al.  Aromatase and its inhibitors: significance for breast cancer therapy. , 2002, Recent progress in hormone research.

[35]  C. Boni,et al.  Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  J. Cuzick,et al.  Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early‐stage breast cancer , 2003, Cancer.

[37]  V. Jordan,et al.  Selective oestrogen receptor modulation , 1999 .

[38]  B. Long,et al.  Predictions from a preclinical model: studies of aromatase inhibitors and antiestrogens. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[39]  S. Hilsenbeck,et al.  A hypersensitive estrogen receptor-alpha mutation in premalignant breast lesions. , 2000, Cancer research.

[40]  M. Dowsett,et al.  Enhanced Estrogen Receptor (ER) α, ERBB2, and MAPK Signal Transduction Pathways Operate during the Adaptation of MCF-7 Cells to Long Term Estrogen Deprivation* , 2003, Journal of Biological Chemistry.

[41]  M. Dowsett,et al.  The pharmacology of letrozole , 2003, The Journal of Steroid Biochemistry and Molecular Biology.

[42]  M. Dowsett,et al.  Comparison of the systemic and intratumoral effects of tamoxifen and the aromatase inhibitor vorozole in postmenopausal patients with primary breast cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  Ji-ping Wang,et al.  Estradiol hypersensitivity and mitogen-activated protein kinase expression in long-term estrogen deprived human breast cancer cells in vivo. , 2000, Endocrinology.

[44]  P. Webb,et al.  Tamoxifen activation of the estrogen receptor/AP-1 pathway: potential origin for the cell-specific estrogen-like effects of antiestrogens. , 1995, Molecular endocrinology.

[45]  Zbigniew Dauter,et al.  Molecular basis of agonism and antagonism in the oestrogen receptor , 1997, Nature.

[46]  M. Brandi,et al.  Polymorphism of the aromatase gene in postmenopausal Italian women: distribution and correlation with bone mass and fracture risk. , 2001, The Journal of clinical endocrinology and metabolism.

[47]  N. Webster,et al.  The human estrogen receptor has two independent nonacidic transcriptional activation functions , 1989, Cell.

[48]  Ji-ping Wang,et al.  Adaptive hypersensitivity to estradiol: potential mechanism for secondary hormonal responses in breast cancer patients , 2001, The Journal of Steroid Biochemistry and Molecular Biology.

[49]  R. Nicholson,et al.  Enhanced epidermal growth factor receptor signaling in MCF7 breast cancer cells after long-term culture in the presence of the pure antiestrogen ICI 182,780 (Faslodex). , 2001, Endocrinology.

[50]  Simak Ali,et al.  Phosphatidylinositol 3-Kinase/AKT-mediated Activation of Estrogen Receptor α , 2001, The Journal of Biological Chemistry.

[51]  C. Boni,et al.  Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[52]  J. Ellenberg,et al.  Cyclic, proteasome-mediated turnover of unliganded and liganded ERalpha on responsive promoters is an integral feature of estrogen signaling. , 2003, Molecular cell.

[53]  A. Wellstein,et al.  Estradiol rapidly activates Akt via the ErbB2 signaling pathway. , 2003, Molecular endocrinology.

[54]  E. Levin,et al.  Proximal Events in Signaling by Plasma Membrane Estrogen Receptors* , 2003, The Journal of Biological Chemistry.

[55]  J. Frasor,et al.  Selective Estrogen Receptor Modulators , 2004, Cancer Research.

[56]  M. Dowsett,et al.  Changes in estrogen receptor, progesterone receptor, and pS2 expression in tamoxifen-resistant human breast cancer. , 1995, Cancer research.

[57]  C K Osborne,et al.  Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[58]  K. Patel,et al.  Prostaglandin E2 production and metabolism in human breast cancer cells and breast fibroblasts. Regulation by inflammatory mediators. , 1995, British Journal of Cancer.

[59]  C. Osborne,et al.  Comparison of estrogen receptor DNA binding in untreated and acquired antiestrogen-resistant human breast tumors. , 1997, Cancer research.

[60]  J. Font de Mora,et al.  AIB1 Is a Conduit for Kinase-Mediated Growth Factor Signaling to the Estrogen Receptor , 2000, Molecular and Cellular Biology.

[61]  F. Cavalli,et al.  First-line fadrozole HCI (CGS 16949A) versus tamoxifen in postmenopausal women with advanced breast cancer. Prospective randomised trial of the Swiss Group for Clinical Cancer Research SAKK 20/88. , 1996, Annals of oncology : official journal of the European Society for Medical Oncology.

[62]  D. Spiegelman,et al.  No association between a single nucleotide polymorphism in CYP19 and breast cancer risk. , 2002, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[63]  T. Key,et al.  Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. , 2002, Journal of the National Cancer Institute.

[64]  M. Dowsett,et al.  Increased activator protein-1 DNA binding and c-Jun NH2-terminal kinase activity in human breast tumors with acquired tamoxifen resistance. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[65]  V. Jordan,et al.  Selective oestrogen receptor modulation: molecular pharmacology for the millennium. , 1999, European journal of cancer.

[66]  N. Harada,et al.  Tissue-specific expression of the human aromatase cytochrome P-450 gene by alternative use of multiple exons 1 and promoters, and switching of tissue-specific exons 1 in carcinogenesis. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[67]  J Cuzick,et al.  Overview of the main outcomes in breast-cancer prevention trials , 2003, The Lancet.

[68]  C. Falkson,et al.  A randomised study of CGS 16949A (fadrozole) versus tamoxifen in previously untreated postmenopausal patients with metastatic breast cancer. , 1996, Annals of oncology : official journal of the European Society for Medical Oncology.

[69]  S. Bulun,et al.  Distribution of aromatase P450 transcripts and adipose fibroblasts in the human breast. , 1996, The Journal of clinical endocrinology and metabolism.

[70]  C. Osborne,et al.  Effect of estrogens and antiestrogens on growth of human breast cancer cells in athymic nude mice. , 1985, Cancer research.

[71]  I. Tannock,et al.  Randomized phase III trial comparing the new potent and selective third-generation aromatase inhibitor vorozole with megestrol acetate in postmenopausal advanced breast cancer patients. North American Vorozole Study Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[72]  W. Carney,et al.  Serum HER-2/neu and response to the aromatase inhibitor letrozole versus tamoxifen. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[73]  M. Dowsett,et al.  Effects of the aromatase inhibitor letrozole on normal breast epithelial cell proliferation and metabolic indices in postmenopausal women: a pilot study for breast cancer prevention. , 2002, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[74]  E. Levin.  Bidirectional signaling between the estrogen receptor and the epidermal growth factor receptor. , 2003, Molecular endocrinology.

[75]  A Howell,et al.  Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. Arimidex Study Group. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[76]  A. Harris,et al.  Tamoxifen versus aminoglutethimide versus combined tamoxifen and aminoglutethimide in the treatment of advanced breast carcinoma. , 1982, Cancer research.

[77]  L. Dirix,et al.  Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. The Exemestane Study Group. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[78]  M. Kerin,et al.  Increased expression of estrogen receptor beta mRNA in tamoxifen-resistant breast cancer patients. , 1999, Cancer research.

[79]  Mike Clarke,et al.  UK and USA breast cancer deaths down 25% in year 2000 at ages 20–69 years , 2000, The Lancet.

[80]  M. Morgan,et al.  Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[81]  A. Børresen-Dale,et al.  A rare CYP19 (aromatase) variant may increase the risk of breast cancer. , 1998, Pharmacogenetics.

[82]  Mike Clarke,et al.  Tamoxifen for early breast cancer: an overview of the randomised trials , 1998, The Lancet.

[83]  J. Mathis,et al.  Structural analysis of the gene encoding human aromatase cytochrome P-450, the enzyme responsible for estrogen biosynthesis. , 1989, The Journal of biological chemistry.

[84]  C. Osborne,et al.  Acquired tamoxifen resistance: correlation with reduced breast tumor levels of tamoxifen and isomerization of trans-4-hydroxytamoxifen. , 1991, Journal of the National Cancer Institute.

[85]  W. Miller,et al.  The importance of local synthesis of estrogen within the breast , 1987, Steroids.

[86]  P. Lønning.  Pharmacology and clinical experience with exemestane , 2000, Expert opinion on investigational drugs.

[87]  S. Hilsenbeck,et al.  Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. , 2003, Journal of the National Cancer Institute.

[88]  C. Laughton,et al.  Binding characteristics of seven inhibitors of human aromatase: a site-directed mutagenesis study. , 1996, Cancer research.

[89]  D. Heitjan,et al.  Estrogen deprivation causes estradiol hypersensitivity in human breast cancer cells. , 1995, The Journal of clinical endocrinology and metabolism.

[90]  D. Agard,et al.  Estrogen receptor pathways to AP-1 , 2000, The Journal of Steroid Biochemistry and Molecular Biology.

[91]  M. Dowsett,et al.  4-hydroxyandrostenedione: a new treatment for postmenopausal patients with breast cancer. , 1992, European journal of cancer.

[92]  P. Darbre,et al.  Insulin-like Growth Factor Receptor Levels Are Regulated by Cell Density and by Long Term Estrogen Deprivation in MCF7 Human Breast Cancer Cells* , 2001, The Journal of Biological Chemistry.

[93]  M. Piccart,et al.  Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

[94]  M. Dowsett,et al.  Molecular changes associated with the acquisition of oestrogen hypersensitivity in MCF-7 breast cancer cells on long-term oestrogen deprivation , 2002, The Journal of Steroid Biochemistry and Molecular Biology.

[95]  L. Demers,et al.  Effect of CGS 20267 on ovarian aromatase and gonadotropin levels in the rat , 1998, Breast Cancer Research and Treatment.

[96]  M. Baum.  Anastozole (A) is superior to tamoxifen (T) in treatment of postmenopausal (PM) women with early breast cancer (EBC) - First results of the ATAC (Arimidex, tamoxifen, alone or in combination) trial (on behalf of the ATAC Trialists' Group) , 2002 .